Unanswered questions: Monoclonal antibodies in the treatment of advanced nonsmall-cell lung cancer

ONCOLOGY

Volumn 24, Issue 13, 2010, Pages

  Gridelli, Cesare ^a   Rossi, Antonio ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; NAVELBINE; PACLITAXEL; PLACEBO; VASCULOTROPIN;

ADVANCED CANCER; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; DEATH; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; HAZARD RATIO; HUMAN; LARGE CELL CARCINOMA; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION;

EID: 78650832227     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Socinski MA, Crowell R, Hensing TE, et al. Treatment of nonsmall-cell lung cancer, stage IV ACCP evidence-based clinical practice guidelines (2nd Edition). Chest. 2007;132:277S-289S. (Pubitemid 47502813)
2. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV nonsmall-cell lung cancer. J Clin Oncol. 2009; 27:6251-6266.
3. DAddario G, Fruh M, Reck M, et al. Metastatic nonsmall-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl. 5):v116-v119.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med. 2006; 355:2542-2550.
5. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAil. J Clin Oncol. 2009; 27:1227-1234.
6. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous nonsmall-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010; 21:1804-1809.
7. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol. 2004; 22:2184-2191.
8. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable nonsmall-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol. 2009;27:1405-1412.
9. Hainsworth J, Compton P, Strickland D, et al. BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) + paclitaxel/carboplatin (PC) as 1st-line treatment for patients (pts) with advanced, previously untreated, squamous nonsmall-cell lung cancer (NSCLC) (Abstract 128). J Thorac Oncol, 2008;3(Suppl.):S281.
10. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with nonsmall-cell lung cancer and brain metastases. J Clin Oncol. 2009;27:5255-5261.
11. Post-authorisation summary of positive opinion for avastin. Available at: http://www.emea.europa.eu/pdfs/human/opinion/Avastin-12112009en.pdf (accessed on October 23, 2010).
12. Label approved on 07/31/2009 for avastin, BLA no. 125085. Available at: http://www.accessdata.fda.gov/drugsatfda-docslabel/2009/125085s0168lbl.pdf (accessed on October 23, 2010).
13. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV nonsmall-cell lung cancer. J Clin Oncol. 2009;27:6251-6266.
14. Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous nonsmall-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010; 11:733-740.
15. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008;14:263-273.
16. Yang K, Wang YJ, Chen XR, et al. Effectiveness and safety of bevacizumab for unresectable nonsmall-cell lung cancer. A meta-analysis. Clin Drug Investig. 2010; 30:229-241.
17. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage nonsmall-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol.2008; 26:60-65.
18. Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous nonsmall-cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol, 2010; Oct 25 [Epub ahead of print].
19. Griesinger F, Pavlakis N, Garrido P, et al. MO19390 (SAiL): safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent non-squamous nonsmall-cell lung cancer (NSCLC) (Abstract C2.6). J Thorac Oncol. 2009; 4 (Suppl 1):S359-S360.
20. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced nonsmall-cell lung cancer. J Thorac Oncol. 2010; 5:1416-1423.
21. Brahmer JR, Gray R, Schiller JH, et al. ECOG 4599 phase III trial of carboplatin and paclitaxel + bevacizumab: Subset analysis of survival by gender (Abstract 7036). J Clin Oncol,2006; 24(18S):373s.
22. Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced nonsmall-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010;28:949-954.
23. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with nonsmall-cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008; 14:1407-1412.
24. Humblet Y: Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother. 2004; 5:1621-1633.
25. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced nonsmall-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525-1531.
26. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced nonsmall-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010; 28:911-917.
27. Thatcher N, Lynch TJ, Butts C, et al. Cetuximab plus platinum-based chemotherapy as 1stline treatment in patients with nonsmall-cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials (Abstract A3.7). J Thorac Oncol. 2009; 4 (suppl 1):S297.
28. Label approved on 07/22/2009 for erbitux, BLA no. 125084. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125084s167lbl.pdf (accessed on October 23, 2010).
29. Assessment report for erbitux, procedure no. EMEA/H/C/558/II/0029. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Assessment-Report-Variation/human/000558/(accessed on October 23, 2010).
30. Gridelli C, Morabito A, Gebbia V, et al. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced nonsmall-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer. 2010; 67:86-92.
31. Lilenbaum R, Wang X, Gu L, et al. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced nonsmall-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol. 2009; 27:4487-4491.
32. Rossi A, Bria E, Maione P, et al. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced nonsmall-cell lung cancer. Rev Recent Clin Trials 2008; 3:217-227.
33. Gatzemeier U, von Pawel J, Vynnchenko I, et al. FLEX: Cetuximab in combination with platinum-based chemotherapy (CT) improves survival versus CT alone in the 1st-line treatment of patients (pts) with advanced nonsmall-cell lung cancer (NSCLC) (Abstract 8). J Thorac Oncol. 2008; 3 (suppl 4):S265-S266.
34. Gatzemeier U, Paz-Ares L, Rodrigues Pereira J, et al. Molecular and clinical biomarkers of cetuximab efficacy: data from the phase III FLEX study in nonsmall-cell lung cancer (NSCLC) (Abstract B2.3). J Thorac Oncol. 2009; 4 (suppl. 1):S324.
35. Obyrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in nonsmall-cell lung cancer (NSCLC): data from the FLEX study (Abstract 8007). J Clin Oncol. 2009; 27(15S):408s.